Xilio Therapeutics Statistics
Want to see XLO full AI Analyst Report?
Xilio Therapeutics (XLO) Stock Statistics & Valuation Metrics
Total Valuation
Xilio Therapeutics has a market cap or net worth of $56.72M. The enterprise value is $56.16M.
- Market Cap
- $56.72M
- Enterprise Value
- $56.16M
Share Statistics
Xilio Therapeutics has 6,580,153 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 6,580,153
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Xilio Therapeutics’s return on equity (ROE) is -0.99 and return on invested capital (ROIC) is -42.09%.
- Return on Equity (ROE)
- -0.99
- Return on Assets (ROA)
- -0.23
- Return on Invested Capital (ROIC)
- -42.09%
- Return on Capital Employed (ROCE)
- -0.43
- Revenue Per Employee
- 575.87K
- Profits Per Employee
- -461.00K
- Employee Count
- 76
- Asset Turnover
- 0.28
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Xilio Therapeutics is -38.77. Xilio Therapeutics’s PEG ratio is -0.09.
- PE Ratio
- -38.77
- PS Ratio
- 4.10
- PB Ratio
- 2.31
- Price to FCF
- -0.97
- Price to Operating Cash Flow
- -2.77
- PEG Ratio
- -0.09
Income Statement
In the last 12 months, Xilio Therapeutics had revenue of 43.77M and earned -35.04M in profits. Earnings per share was -4.19.
- Revenue
- 43.77M
- Gross Profit
- 42.23M
- Operating Income
- -41.98M
- Pretax Income
- -35.04M
- Net Income
- -35.04M
- EBITDA
- -33.49M
- Earnings Per Share (EPS)
- -4.19
Cash Flow
In the last 12 months, operating cash flow was -56.90M and capital expenditures -728,000, giving a free cash flow of -57.63M billion.
- Operating Cash Flow
- -56.90M
- Free Cash Flow
- -57.63M
- Free Cash Flow per Share
- -3.12
Dividends & Yields
Xilio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -103.57%
- Earnings Yield
- 6.23%
Stock Price Statistics
- Beta
- 0.40
- 52-Week Price Change
- -25.96%
- 50-Day Moving Average
- 8.74
- 200-Day Moving Average
- 8.49
- Relative Strength Index (RSI)
- 52.68
- Average Volume (3m)
- 12.21K
Important Dates
Xilio Therapeutics upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 03, 2027
- Ex-Dividend Date
- ―
Financial Position
Xilio Therapeutics as a current ratio of 2.58, with Debt / Equity ratio of 19.71%
- Current Ratio
- 2.58
- Quick Ratio
- 2.58
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 3.90
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Xilio Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Xilio Therapeutics EV to EBITDA ratio is 3.71, with an EV/FCF ratio of 1.03.
- EV to Sales
- -4.61
- EV to EBITDA
- 3.71
- EV to Free Cash Flow
- 1.03
- EV to Operating Cash Flow
- 1.04
Balance Sheet
Xilio Therapeutics has $122.18M in cash and marketable securities with $5.96M in debt, giving a net cash position of $116.22M billion.
- Cash & Marketable Securities
- $122.18M
- Total Debt
- $5.96M
- Net Cash
- $116.22M
- Net Cash Per Share
- $17.66
- Tangible Book Value Per Share
- ―
Margins
Gross margin is 100.00%, with operating margin of -300.95%, and net profit margin of 75.70%.
- Gross Margin
- 100.00%
- Operating Margin
- -300.95%
- Pretax Margin
- 75.70%
- Net Profit Margin
- 75.70%
- EBITDA Margin
- -119.05%
- EBIT Margin
- -40.49%
Analyst Forecast
The average price target for Xilio Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 327.25%
- EPS Growth Forecast
- 85.65%
Scores
- Smart Score
- 2
- AI Score
- 47
